Sort
4,870 grants matching “glp 1”
rVSV Vectored Vaccine to Protect Against Ebola and Marburg Viruses
$937,397John H Eldridge · Profectus Biosciences, Inc. · R01 · FY2014 · AI
A New Anti-inflammatory Therapy for Ischemic Stroke
$934,548Bruce Liang · Cornovus Pharmaceuticals, Inc. · R42 · FY2024 · HL
Translational Development of a Targeted and Stroma-penetrating Nanoparticle Drug for Pancreatic Cancer Therapy
$934,438Lei Zhu · Migra-Therapeutics, Llc · R44 · FY2022 · CA
Microneedle Based Targeted Allergen Specific Immunotherapy for Treatment of Peanut Allergies
$934,422Samirkumar Patel · Moonlight Therapeutics, Inc. · R42 · FY2021 · AI
Topical Eyedrops Increasing Lysyl Oxidase and Dopamine Activity to Control Myopia
$933,817Sarah Abdulla Molokhia · Iveena Delivery Systems, Inc. · R44 · FY2025 · EY
National Gene Vector Biorepository and Coordinating Center at Indiana University
$933,175Lilith Reeves · Indiana University Indianapolis · P40 · FY2014 · HL
A Yeast-based Immunotherapy against Clostridioides difficile infection
$932,749Zhiyong Yang · Fzata, Inc. · R44 · FY2022 · AI
Design and Validation of Easy-to-Adopt Mass Spectrometry Assays of Importance to Obesity
$932,618Jennifer E Van Eyk · Cedars-Sinai Medical Center · U01 · FY2019 · DK
Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC
$930,592Cathy A Swindlehurst · Novomedix, Inc. · R44 · FY2023 · HL
An Improved Method of Delivering a Sclerosing Agent for the Treatment of a Malignant Pleural Effusion.
$930,483Glenn W Laub · Tdl Innovations, Llc · R44 · FY2019 · CA
Development of Sudaxine for the Treatment of Opioid Induced Respiratory Depression (OIRD) in the Peri-operative Hospital Setting
$928,464James N Bates · Atelerix Life Sciences Inc. · R44 · FY2023 · HL
A novel monobody-drug conjugate to treat mutant Ras multiple myeloma
$928,011Craig Patrick Ramirez · Tezcat Laboratories Llc · R44 · FY2024 · CA
Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer
$927,566Sudhir Sahasrabudhe · Jsk Therapeutics, Inc. · R44 · FY2012 · CA
First-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form Development
$925,560Gunnar Joerg Floris Kaufmann · Oncternal Therapeutics, Inc. · R44 · FY2021 · CA
Development of a TRAIL-based therapy for alcohol related chronic pancreatitis
$924,849Victor V Roschke · Theraly Fibrosis, Inc. · U44 · FY2017 · AA
National Gene Vector Biorepository and Coordinating Center at Indiana University
$924,033Kenneth G Cornetta · Indiana University Indianapolis · P40 · FY2015 · HL
Efficient Distribution of Human Embryonic Stem Cells
$923,513Bresagen, Inc. · R24 · FY2002 · DK
Development of the first HRV vaccine
$923,094Gregory John Tobin · Biological Mimetics, Inc. · R44 · FY2014 · AI
A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis
$922,693Gary Fanger · Rise Therapeutics, Llc · R44 · FY2023 · AI
Sustained release gel enabling one-stage treatment of prosthetic joint infection
$919,432Derek James Overstreet · Sonoran Biosciences, Inc. · R44 · FY2017 · AR
PIC1 pre-clinical formulation and optimization as a novel anti-inflammatory pharmacological agent
$919,171Neel Kumar Krishna · Realta Life Sciences, Inc. · R44 · FY2019 · AI
Ligand-Directed KRAS G12V Mutant-Specific Therapeutics
$919,020Lyla Stanland · Enfuego Therapeutics Inc. · R44 · FY2024 · CA
Ligand-Directed KRAS G12V Mutant-Specific Therapeutics
$919,020Lyla Stanland · Enfuego Therapeutics Inc. · R44 · FY2025 · CA
Microneedle Based Targeted Allergen Specific Immunotherapy for Treatment of Peanut Allergies
$918,854Samirkumar Patel · Moonlight Therapeutics, Inc. · R42 · FY2022 · AI
A single dose anti-scarring therapeutic for the cornea
$917,935Tere M. Williams · Dub Therapeutics Inc. · R44 · FY2024 · EY